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The telomerase reverse transcriptase (TERT) was 
discovered in the beginning of 1980s. This enzyme is able 
to preserve the chromosomes integrity by adding to their 
ends a specific nucleotide sequences called “telomeres” (1,2). 
To date, it is also well established that TERT plays a crucial 
role in the immortalization and proliferation of malignant 
cells in several type of cancers, thyroid cancer (TC) included 
(3,4). The most common TERT mutations identified among 
TC are C288T and C250T. A recent review has shown that 
10% of evaluated TC, of different types, harboured TERT 
mutations: 86.1%, C228T; 12%, C250T; 2.1% other types. 
The prevalence was higher among the most aggressive 
subtypes of TC with the highest value in the anaplastic TC 
(56.8%). In fact a significant association has been reported 
between TERT mutations and: older age, larger tumor size, 
extrathyroidal invasion, lymph node or distant metastases, 
TNM stage, or recurrence. TERT promoter mutations 
might also be present in BRAF V600E positive TC. Patients 
affected by tumors with these two combined mutations 
have poorer prognosis and outcomes (5). These data are 
supported by a meta-analysis, which showed that papillary 
thyroid cancers (PTCs) harbouring both BRAF and TERT 
promoter mutations, are more aggressive than those with 
BRAF, or TERT promoter mutations, alone. By specifying 
the BRAF and TERT promoter mutations status, PTCs can 
be classified into four distinct risk groups with decreasing 
aggressiveness as follows: BRAF and TERT mutations, 
TERT mutation only, BRAF mutation only, or absence of 
both (6).
Through the cellular samples obtained by fine needle 
aspiration (FNA) of thyroid nodules, it is possible to define 
the molecular profile of the sampled thyroid nodules, 
improving their diagnosis and management. BRAF V600E 
is the most studied and experienced mutation of cancer for 
thyroid nodule due to its high specificity. The diagnostic 
yield can be augmented testing FNA samples for more 
mutations associated with TC such as TERT, BRAF, PAX8/
PPARγ, RAS, and RET/PTC: thyroid nodules found with any 
of these mutations have a higher chance to be malignant. 
Thus the molecular profiling of thyroid nodules, especially 
if with indeterminate cytology at the FNA, is a helpful tool 
for their clinical management (7,8). 
Bournaud et al. (9) studied the prognostic value of 
TERT promoter mutations in TC. They enrolled in a 
prospective study [2010–2013], 173 patients affected 
by differentiated TC [pT3 >20 mm, pT4 or M1; 2004 
World Health Organization]. All patients were treated 
with total (or near total) thyroidectomy, plus lymph 
node dissection, (when indicated) and radioiodine (RAI) 
therapy. Follow-up and therapies adhered to American 
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Thyroid Association (ATA) guidelines [2009] (10,11). The 
subjects were restaged according to system defined by 
Tuttle et al. (12), and the new ATA guidelines [2016] (13). 
Patients were considered: (I) in remission when classified 
as excellent, or indeterminate response, after the first 
treatment; (II) whereas as having persistent disease, in those 
having biochemical, or structural incomplete response. 
Subsequently, once a year, thyroglobulin (Tg), and cervical 
ultrasonography (and when appropriate also other imaging), 
were obtained to update the oncological status of patients, 
up to 5 years. The patients were classified as having: (I) no 
evidence of disease (NED) (Tg <1 mg/L, negative AbTg, 
no structural evidence of TC) (13); (II) recurrent disease 
(biological; morphological; local; or metastatic). Deaths 
due or not to cancer, were registered. Mutations of TERT 
promoter, of BRAF exon 15, HRAS exon 3, NRAS exon 3 
were evaluated in all tumors. TERT promoter mutations 
were present in 20.2% TC (the prevalence was higher in 
tumors with histological aggressive features, than in non-
aggressive: 32.7%, vs. 15.3%, respectively). TERT mutations 
were also more frequently reported among patients older 
than 45 years, pT4 stage cancers, metastatic, or with 
extrathyroidal invasion. A poor prognosis was associated 
with TERT mutations in all the patients (P<0.001), but not 
in non-metastatic. In particular, in non-metastatic patients 
event-free survival was related with age ≥45, histological 
aggressive features and vascular invasion.
BRAF mutation was detected in 50 tumors (28.9%) with 
no significant difference between aggressive (24.5%) and 
non-aggressive tumors (30.6%), whereas RAS mutation 
was found in 27 TC (15.6%) (NRAS, 17; HRAS, 10). The 
association of TERT and BRAF was found in 7.5% TC, 
and of RAS and TERT 5.2%. Event-free survival was not 
related with these mutations in all patients. In multi-variate 
analysis, histological aggressive characteristics were linked 
to worse event-free survival. TERT mutations were strongly 
associated with a poorer prognosis in subjects with no 
metastases and aggressive histological features (9); but not 
BRAF, or RAS. 
BRAF V600E has been associated, by several data, with 
aggressive behavior of PTC: recurrence; RAI refractory 
TC; extrathyroidal extension; and lymph node metastases 
(14,15). PTC-specific mortality was associated with BRAF 
V600E in a study on 1,849 patients (16). These and other 
studies suggested an important tumorigenic role of BRAF 
V600E in the aggressiveness, or progression, of PTC. 
However, other studies were also reported that did not find 
any association with features of TC aggressiveness (4,17,18). 
Most of previous studies assessed the impact of TERT, on 
long-term outcomes, finding an association with high death 
risk, or of RAI courses (19,20). On the other hand, the 
Bournaud’s study had evaluated the patient status every year, 
during the follow-up (9). With their study, Bournaud et al. 
showed that TERT mutations were related with incomplete 
response (after the initial therapy), and a lower NED after 
5 years, even in initially non-metastatic patients, supporting 
a closer monitoring and more aggressive treatment of these 
patients (9). According to these data, few years ago, Xu et al. 
reported a retrospective study of patients with PTC, with 
initial low-risk histological features, and TERT mutations, 
subsequently developing metastatic disease (21).
In conclusion, TERT mutations may do not have a better 
prognostic value than histology, but they have been linked 
to a worse prognosis in metastasis-free patients without 
aggressive histological characteristics. For this reason 
patients affected by TC harbouring TERT mutations may 
benefit from a more intensive follow-up, and treatment. 
More studies in larger number of TC patients are needed to 
confirm the results of the Bournaud’s paper, but its research 
could represent a promising advancement in identifying 
metastasis free TC patients deserving a more intensive 
follow-up, and treatment (9).
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